BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Werewolf Therapeutics,

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merge

$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, T

Werewolf Therapeutics (HOWL) stock exploded higher on Friday morning after management said the compa

Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's

Dow gains 400 points, Materials sector up 2.3%, Werewolf Therapeutics up 113%, S&P PMI rises to

US stocks rise, Dow gains over 350 points as markets open Friday; Materials sector up 2%, utilitie

Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was one of the market's biggest pre-market movers on Frida

Werewolf Therapeutics surged after announcing a $500 million merger with Ambros Therapeutics, puttin

Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares moved upwards by 74.6% to $0.75 during Friday&#3

WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq:

Ross Stores beats estimates with Q2 financial results, shares jump 9.1%. Other gainers include RFAI,

Werewolf Therapeutics shares surge 89.94% after hours as $33 million deal with EMD Serono brings fre

Gainers Werewolf Therapeutics (NASDAQ:HOWL) stock moved upwards by 77.1% to $0.76 during Thursday&#

Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's af

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly earnings of $0.08 per share which beat the an

WATERTOWN, Mass., July 31, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “W

Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular

Shares of elf Beauty Inc (NYSE: ELF) rose sharply in pre-market trading after beating analyst expect

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.28) per share which met the ana

WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “We

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.20) per share which beat the an

Company continues to evaluate strategic options to maximize shareholder value Company continues to e

Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the "Company" or "Werewolf"), an innovat

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the

Shares of Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) have earned a consensus recom

Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) Director Luke Evnin sold 24,678 shares

Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) Director Luke Evnin sold 24,962 shares

Werewolf Therapeutics, Inc. (NASDAQ: HOWL - Get Free Report) Director Luke Evnin sold 18,568 shares

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Werewolf Therapeutics (NASDAQ:HOWL)

WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a d

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism

Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of

– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S.

Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, whi

Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.

Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that i